🇺🇸 FDA
Patent

US 12194049

Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection

granted A61KA61K31/43A61K31/546

Quick answer

US patent 12194049 (Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection) held by GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD
Grant date
Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/43, A61K31/546, A61P, A61P31/00